Freda Biological

About Freda Biological

Shandong Freda Biotechnology Co., Ltd., established in 2008, operates as a key enterprise under the Lushang Freda Pharmaceutical Co., Ltd. umbrella, focusing on the industrialization of synthetic biology fermentation raw materials. The company directs its research, development, and sales efforts toward creating ingredients for the cosmetics, food, health products, and pharmaceutical sectors. Its business-to-business model serves a global client base, supplying a diverse portfolio of functional active ingredients.

The company's offerings are segmented into two primary categories. For the food industry, Freda Biological produces additives like natamycin, nisin, and ε-polylysine, alongside functional ingredients such as γ-aminobutyric acid and various extracts. In the cosmetics realm, the company leverages synthetic biology and fermentation technology to produce sought-after raw materials including ectoin, sodium polyglutamate, and pro-xylane. Additionally, the firm is advancing its research into recombinant collagen and extracts specialized ingredients like Centella asiatica through proprietary processes. Freda Biological has secured multiple international quality certifications, including ISO9001, ISO22000, BRC, and FDA, underpinning its commitment to global standards.

Strategically, Freda Biological has achieved significant regulatory milestones that enhance its market position. The company's independently developed natamycin received U.S. FDA Drug Master File (DMF) certification, opening pathways in the pharmaceutical space. More recently, in 2024, its sodium polyglutamate for medical devices completed Master File registration with China's NMPA, a first for this type of raw material in the country. These achievements highlight the company's technical capabilities and its focus on high-value, regulated markets.